Ampersand Biomedicines

What Ampersand Biomedicines does

Ampersand Biomedicines is a privately held, preclinical-stage biotechnology company developing programmable medicines designed to act exclusively at the site of disease. Founded in 2021 at Flagship Labs (Flagship Pioneering's innovation foundry) and headquartered in Boston, the company operates a multi-product platform built around its proprietary Address, Navigate, Determine (AND) Platform, which uses a computational engine together with a proprietary multi-omics Address Map to identify ideal tissue- and cell-specific localizing targets. On this foundation, Ampersand engineers AND-Body Therapeutics—modular medicines that combine a localizing element with a disease-modifying actuator (proteins, small molecules, LNPs, or nucleic acids) intended to engage disease biology while sparing healthy tissue.

The company's internal pipeline is concentrated in two lead candidates: AMP-220, a gut-targeted IL-22 therapeutic for inflammatory bowel disease, and AMP-410, an anti-VEGF/4-1BB bifunctional for solid tumors (melanoma, colorectal, lung). Both were reported to be in IND-enabling studies in 2025. Through the January 2024 acquisition of AbCheck s.r.o. (now Ampersand CZ, based in Plzeň, Czech Republic), Ampersand added integrated antibody discovery capabilities including microfluidics, rabbit mass humanization, and phage/yeast display libraries validated through more than 45 biopharma partnerships. The business model is pre-commercial, with future revenue expected to derive from licensing the AND Platform and proprietary Address Map, co-development partnerships, and milestone/royalty payments on partnered or out-licensed programs.

Ampersand pursues an enterprise B2B go-to-market, evidenced by strategic partnerships with Pfizer (obesity, via Pioneering Medicines, November 2024), Genethon (AAV vector tissue specificity for gene therapy, May 2026), and Eli Lilly's participation as a strategic investor in the March 2025 $65M Series B. Total funding raised is $115 million across two rounds ($50M from Flagship Pioneering in March 2023 and $65M led by Flagship and Eli Lilly in March 2025). The company has 11–50 employees across its Boston headquarters and Czech R&D subsidiary.

Name

Ampersand Biomedicines

Legal name

Ampersand Biomedicines

Website

https://ampersand.bio

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Ampersand Biomedicines is a preclinical-stage biotechnology company that uses its proprietary AND computational platform and multi-omics Address Map to engineer programmable AND-Body therapeutics for tissue-selective treatment of inflammatory and oncologic diseases, serving pharmaceutical partners through licensing and co-development deals.

Ownership category

akta.pro rank

Product category

Programmable Biologic Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Programmable biologics platform
• Targeted antibody therapeutics
• Multi-omics drug discovery
• Tissue-specific therapeutics
• Biologics platform licensing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Platform Licensing and Co-development: Pre-commercial stage biotech. Revenue expected through licensing AND-Body platform technology, co-development partnerships with pharmaceutical companies, and potential milestone payments and royalties from partnered programs.
2. Internal Pipeline Development: Developing proprietary AND-Body Therapeutics in immuno-inflammation and immuno-oncology. Potential value capture through out-licensing or acquisition of developed programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ampersand Biomedicines develops programmable, multi-specific biologic medicines called AND-Body Therapeutics, designed via its proprietary AND (Address, Navigate, Determine) Platform and Address Map to localize at disease sites and act only where needed. The company's current sellable pipeline includes AMP-220, a gut-targeted IL-22 therapeutic for inflammatory bowel disease, and AMP-410, a first-in-class anti-VEGF/4-1BB bifunctional for solid tumors, both in IND-enabling studies, supported by an in-house antibody discovery operation (Ampersand CZ, formerly AbCheck).

Product overview

Ampersand Biomedicines is a multi-product platform company developing programmable biologics through its proprietary AND™ (Address, Navigate, Determine) Platform. The core platform, powered by a computational engine and the proprietary Address Map, identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics—a new category of programmable, multi-specific medicines that combine tissue-specific localizers with disease-modifying actuators. The company operates alongside its wholly-owned subsidiary AbCheck, which provides antibody discovery capabilities including microfluidics, rabbit mass humanization, and display libraries. The current pipeline includes lead programs AMP-220 (a gut-targeted IL-22 therapeutic for IBD) and AMP-410 (an anti-VEGF/4-1BB bifunctional therapeutic for cancer), both designed to act exclusively at disease sites to improve efficacy and tolerability.

Differentiator

Problem solved

Functional benefit

Products and services

• AND™ Platform Computationally powered drug discovery platform that identifies ideal addresses for drug localization and informs the design of AND-Body Therapeutics. Combines a proprietary multi-omics Address Map with binder generation, AI-guided prediction, and integrated modeling and screening. Licensed/co-developed with pharmaceutical partners.
• AND-Body™ Therapeutics Programmable, multi-specific medicines that combine a localizing element (anchoring the medicine in diseased tissue) with an actuator moiety (signaling to restore healthy biology), designed to act only at disease sites. Constructed across formats including proteins, small molecules, LNPs, and nucleic acids.
• Address Map Proprietary computational atlas based on comprehensive multi-omics characterization of human biology that identifies optimal addresses for drug localization with cell-specific precision, serving as the foundation for every AND-Body therapeutic.
• AbCheck Antibody Discovery Platform Cutting-edge antibody discovery platform with technologies including microfluidics, rabbit mass humanization, and phage/yeast display libraries. Over 15 years of validated capabilities through 45+ partnerships with biopharma companies producing multiple clinical candidates. Operates as Ampersand CZ.
• AMP-220 Lead gut-targeted IL-22 AND-Body therapeutic for inflammatory bowel disease, combining a gut epithelium-specific localizer with an engineered IL-22 mutein that is conditionally active only upon co-localization to the gut, with up to 2,000-fold greater potency versus non-targeted IL-22 control in vitro.
• AMP-410 Lead first-in-class bifunctional anti-VEGF/4-1BB AND-Body therapeutic activated only by VEGF signals in tumors that binds 4-1BB on immune cells to drive anti-tumor immune response, with 90% tumor-free survival in a colorectal cancer model as monotherapy and 100% tumor-free survival combined with anti-PD-1.

Quantifiable outcome

• Up to 2,000-fold greater potency versus non-targeted IL-22 control in vitro for AMP-220
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• GenethoncoreStrategic or Co-development Partner · 21 May 2026Exclusive collaboration to engineer novel AAV vectors with enhanced tissue specificity for gene therapy. Leverages Ampersand's tissue-specific ligands to drive vector specificity, with Genethon integrating localizers onto AAV capsid surfaces. Initially focused on skeletal muscle with intent to expand across tissues. Combines Ampersand's targeting capabilities with Genethon's gene therapy expertise.
• Pioneering MedicinescoreStrategic or Co-development Partner · 19 March 2025Flagship Pioneering's in-house drug discovery unit leading partnership with Pfizer. Discovery partnership with Ampersand focused on obesity treatment, leveraging Ampersand's AND-Body platform for tissue-selective metabolic pathway targeting.
• PfizercoreStrategic or Co-development Partner · 20 November 2024Partnership under Flagship Pioneering's strategic partnership with Pfizer. Ampersand's AND Platform being used to identify programmed biologics for treatment of obesity-related targets. Leverages Pfizer's deep expertise in early discovery and development for cardiometabolic treatments.
• AbCheck s.r.o.coreTechnology or Integration · 3 January 2024Acquired by Ampersand to enhance in-house antibody discovery capabilities. AbCheck's platform includes microfluidics, rabbit mass humanization, phage/yeast display libraries. Validated through 45+ partnerships producing multiple clinical candidates. Now operates as Ampersand CZ.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies designed to improve therapeutic index through tumor-targeted delivery. Comparable therapeutic thesis to Ampersand's tissue-specific delivery approach for cancer.
• BigHat Biosciences: Early-stage antibody design company combining ML with high-throughput wet-lab experimentation to engineer next-generation antibodies. Comparable in the AI-guided antibody engineering stack that Ampersand uses in its 'Navigate' (binder generation) capability.

Direct peers

• Generate Biomedicines: Flagship Pioneering-founded company developing AI-designed generative protein therapeutics. Most directly comparable peer: sister Flagship company using computational/AI platforms to engineer novel protein medicines, overlapping with Ampersand's AI-guided binder and AND-Body engineering approach.
• Compass Therapeutics: Clinical-stage oncology biotech developing bispecific antibodies (e.g., CTX-009 anti-DLL4/VEGF, CTX-1121 CD20xCD3) including immune engagers for solid tumors. Comparable to AMP-410 in the bispecific oncology space and shares Ampersand's logic of combining targeting with immune activation.
• CytomX Therapeutics: Developer of the Probody platform — conditionally activated antibody therapeutics designed to be inert in healthy tissue and activated in disease. Direct peer to Ampersand's conditional-activation AND-Body concept, with several clinical-stage assets (e.g., pacmilimab) validating the activation-masking approach.
• Adagene: Clinical-stage biotech developing antibody-based therapeutics using its POWER platforms (including SAFEbody masking technology for conditional activation). Direct peer in conditionally activated antibody engineering, with clinical assets in oncology.
• Janux Therapeutics: Develops T cell engagers (TCEs) — bispecific antibodies designed to be activated preferentially in the tumor microenvironment, leveraging masking/conditional activation to reduce systemic toxicity. Direct peer to Ampersand's tissue-restricted bispecific strategy in immuno-oncology.
• Werewolf Therapeutics: Develops PREDATOR platform — conditionally activated immune engagers and cytokines that are masked until they reach the tumor microenvironment. Direct peer in tissue-specific biologic activation, with INDUKINE assets (e.g., WTX-124) in clinical development for oncology.
• AbCellera Biologics: Antibody discovery platform company combining high-throughput microfluidics, AI/ML, and a data-rich technology stack to discover therapeutic antibodies. Closely comparable to Ampersand's AbCheck subsidiary in technology approach and B2B partnership model with pharma.
• BioAtla: Develops Conditionally Active Biologics (CABs) — antibodies and other proteins engineered to be active only in disease microenvironments (e.g., low pH, high protease activity). Closely comparable mechanism to Ampersand's tissue-restricted activation thesis, with clinical-stage assets in oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AmpersandBio
• LinkedInlinkedin.com/company/ampersand-biomedicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ampersand Biomedicines